[1] 张洪林,律正严,李海蓉. 滋阴活血汤恩替卡韦治疗代偿期乙型肝炎肝硬化的临床效果[J]. 国际医药卫生导报,2017,23(7):1065-1067. DOI:10.3760/cma.j.issn.1007-1245. 2017.07.046.
[2] Ginès P, Krag A, Abraldes JG, et al. Liver cirrhosis[J].Lancet,2021,398(10308):1359-1376. DOI:10.1016/S0140- 6736(21)01374-X.
[3] Lee NY, Suk KT. The role of the gut microbiome in liver cirrhosis treatment[J]. Int J Mol Sci,2020,22(1):199. DOI:10.3390/ijms22010199.
[4] Suk KT, Kim DJ. Gut microbiota: novel therapeutic target for nonalcoholic fatty liver disease[J]. Expert Rev Gastroenterol Hepatol,2019,13(3):193-204. DOI:10.1080/17474124.2019.1569513.
[5] GBD 2017 Cirrhosis Collaborators. The global, regional, and national burden of cirrhosis by cause in 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017[J]. Lancet Gastroenterol Hepatol,2020,5(3):245-266. DOI:10.1016/S2468-1253(19)30349-8.
[6] 张露,范志芳,刘殿武,等.1990-2016年中国乙型肝炎引起的肝硬化及其他慢性肝病疾病负担变化趋势分析[J].中华流行病学杂志,2020,41(2):173-177. DOI:10.3760/cma.j.issn.0254-6450.2020.02.007.
[7] Albillos A, de Gottardi A, Rescigno M. The gut-liver axis in liver disease: pathophysiological basis for therapy[J]. J Hepatol,2020,72(3):558-577. DOI:10.1016/j.jhep.2019. 10.003.
[8] Huang W, Kong D. The intestinal microbiota as a therapeutic target in the treatment of NAFLD and ALD[J]. Biomed Pharmacother,2021,135:111235. DOI:10.1016/j.biopha.2021.111235.
[9] Hu H, Lin A, Kong M, et al. Intestinal microbiome and NAFLD: molecular insights and therapeutic perspectives[J]. J Gastroenterol,2020,55(2):142-158. DOI:10.1007/s00535-019-01649-8.
[10] Chen J, Vitetta L. Gut microbiota metabolites in NAFLD pathogenesis and therapeutic implications[J]. Int J Mol Sci,2020,21(15):5214. DOI:10.3390/ijms21155214.
[11] 唐源淋,陈烨. 肠道菌群失衡与肝硬化分级及预后的关系[J]. 现代消化及介入诊疗,2019,24(1):11-15. DOI:10.3969/j.issn.1672-2159.2019.01.004.
[12] 唐源淋,陈烨. 定量分析肠道菌群失衡与肝硬化病情的关系[J]. 胃肠病学,2020,25(4):199-203. DOI:10.3969/j.issn.1008-7125.2020.04.002.
[13] 中华医学会肝病学分会. 肝硬化诊治指南[J]. 临床肝胆病杂志,2019,35(11):2408-2425. DOI:10.3969/j.issn.1001- 5256.2019.11.006.
[14] Aron-Wisnewsky J, Warmbrunn MV, Nieuwdorp M, et al. Nonalcoholic fatty liver disease: modulating gut microbiota to improve severity?[J]. Gastroenterology,2020,158(7):1881-1898. DOI:10.1053/j.gastro.2020. 01.049.
[15] Chen J, Thomsen M, Vitetta L. Interaction of gut microbiota with dysregulation of bile acids in the pathogenesis of nonalcoholic fatty liver disease and potential therapeutic implications of probiotics[J]. J Cell Biochem,2019,120(3):2713-2720. DOI:10.1002/jcb. 27635.
[16] Safari Z, Gérard P. The links between the gut microbiome and non-alcoholic fatty liver disease (NAFLD)[J]. Cell Mol Life Sci,2019,76(8):1541-1558. DOI:10.1007/s00018- 019-03011-w.
[17] Philips CA, Augustine P. Gut barrier and microbiota in cirrhosis[J]. J Clin Exp Hepatol,2022,12(2):625-638. DOI:10.1016/j.jceh.2021.08.027.
[18] 魏凯艳,黄胡萍,林爱萍,等. 肝硬化患者肠道菌群的初步分析及肠型分析[J]. 胃肠病学和肝病学杂志,2022,31(2):158-164. DOI:10.3969/j.issn.1006-5709.2022.02.008.
[19] 李玉珍,孙元培,廉晓晓,等. 不同病因肝硬化患者肠道菌群变化研究[J]. 中西医结合肝病杂志,2022,32(4):306-310. DOI:10.3969/j.issn.1005-0264.2022.04.006.
[20] 张雯,彭琼. 乙肝肝硬化患者肠道菌群与肝功能及血清炎症因子水平的关系[J]. 现代消化及介入诊疗,2020,25(2):158-162. DOI:10.3969/j.issn.1672-2159.2020.02.006.
[21] Dubinkina VB, Tyakht AV, Odintsova VY, et al. Links of gut microbiota composition with alcohol dependence syndrome and alcoholic liver disease[J]. Microbiome,2017,5(1):141. DOI:10.1186/s40168-017-0359-2.
[22] 张红霞,蔡王锋,李燕妮,等. 肠屏障在自身免疫性肝炎发病中的作用[J]. 中华消化杂志,2020,40(1):9-15. DOI:10.3760/cma.j.issn.0254-1432.2020.01.003.
[23] 陈瑶,向正国,李科军,等. 肝硬化患者肝功能分级与其肠道微生态的相关性研究[J]. 广西医科大学学报,2017,34(7):1006-1009. DOI:10.16190/j.cnki.45-1211/r.2017.07.014.
[24] 戚励,裴冬梅,杨惠,等. 恩替卡韦联合美常安对乙型肝炎肝硬化患者肠道菌群及肠黏膜通透性的影响[J]. 实用临床医药杂志,2020,24(6):61-65. DOI:10.7619/jcmp.202006017.
[25] 廉晓晓,孙元培,郭晓霞. 肝硬化患者肠道黏膜通透性与预后的相关性研究[J]. 中华肝脏病杂志,2020,28(1):58-63. DOI:10.3760/cma.j.issn.1007-3418.2020.01.014.
|